Surveillance Summary March 20 – 26, 2004
March 26, 2004 by admin · Leave a Comment
Our emerging health technology database experienced light activity throughout Week 13 of 2004 with 14 technology updates. 1 High Impact Technology, 8 Moderate Impact Technologies, and 5 Low Impact Technologies were updated. The mean impact score for the week was 40, up three from last week. Of note, 6 of the updated technologies were newly detected during Week 13. The diseases targeted by this week’s technologies were varied with no dominant pathology evident. Please see the table below for this week’s top ten technologies to watch.
Week at a Glance
Technologies updated this week in the BioHorizon database
Technology Company Target Disease Score
Enoximone Myogen CHF 67/100
Velac® Connetics Corporation Acne 62/100
OraQuick® OraSure Technologies HIV 56/100
Periostat CollaGenex Rosacea 50/100
INKP-102 InKine Pharmaceuticals Colon Disease 49/100
Fontolizumab Protein Design Labs Crohn’s Disease 39/100
Nuvion® Protein Design Labs Ulcerative Colitis 35/100
Fosrenol® Shire Pharmaceuticals Hyperphosphatemia 35/100
Anidulafungin Vicuron Pharmaceuticals Aspergillosis 35/100
Pirfenidone Intermune IPF 31/100
